SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yock Young Dan, John B. Wong, Saeed S. Hamid, Kwang-Hyub Han, Ji Dong Jia, Chun-Jen Liu, Teerha Piratvisuth, Anna S. F. Lok, Seng Gee Lim, Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries, Hepatology International, 2014, 8, 3, 382

    CrossRef

  2. 2
    Ming-Ling Chang, Yun-Fan Liaw, Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management, Journal of Hepatology, 2014,

    CrossRef

  3. 3
    Li-Fu Kuo, Chuan-Mo Lee, Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Sheng-Nan Lu, Chi-Sin Changchien, Chien-Hung Chen, High Risk of Hepatitis B Virus Reactivation in Nucleos(t)ide Analogue-Induced Hepatitis B e Antigen Seroconverters Older Than 40 Years, Digestive Diseases and Sciences, 2014, 59, 10, 2580

    CrossRef

  4. 4
    Hyun Woong Lee, Wonseok Kang, Sang Hoon Ahn, Heon Ju Lee, Jae Seok Hwang, Joo Hyun Sohn, Jae Young Jang, Ki Jun Han, Ja Kyung Kim, Do Young Kim, Yong Han Paik, Chun Kyon Lee, Ik-Seong Choi, Kwan Sik Lee, Kwang-Hyub Han, Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients, Journal of Gastroenterology and Hepatology, 2014, 29, 5
  5. 5
    Suna Yapali, Nizar Talaat, Anna S. Lok, Management of Hepatitis B: Our Practice and How It Relates to the Guidelines, Clinical Gastroenterology and Hepatology, 2014, 12, 1, 16

    CrossRef

  6. 6
    Hyung Sohn, Bo Min, Joon Song, Mun Seong, Sang Lee, Eun Jang, Cheol Shin, Young Park, Jin-Hyeok Hwang, Sook-Hyang Jeong, Nayoung Kim, Dong Lee, Jin-Wook Kim, Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs, BMC Infectious Diseases, 2014, 14, 1, 439

    CrossRef

  7. 7
    Chien-Hung Chen, Sheng-Nan Lu, Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Chi-Sin Changchien, Chuan-Mo Lee, The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment, Journal of Hepatology, 2014, 61, 3, 515

    CrossRef

  8. 8
    Rosa María Martín-Mateos, Víctor F. Moreira Vicente, Luis Téllez-Villajos, Concepción García-Sánchez, María Teresa Maroto-Castellanos, Francisco Javier García-Alonso, María Luisa Mateos-Lindemann, Agustín Albillos, Tratamiento de la hepatitis crónica B antígeno e positiva con antivirales orales: experiencia y resultados en la práctica clínica, Gastroenterología y Hepatología, 2014, 37, 5, 280

    CrossRef

  9. 9
    Yongyin Li, Shiwu Ma, Libo Tang, Yun Li, Wei Wang, Xuan Huang, Qintao Lai, Mingxia Zhang, Jian Sun, Chris Kafai Li, William G.H. Abbott, Nikolai V. Naoumov, Yu Zhang, Jinlin Hou, Circulating chemokine (C-X-C Motif) receptor 5+CD4+ T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection, Hepatology, 2013, 58, 4
  10. 10
    Cheng-Yuan Peng, Tsung-Cheng Hsieh, Tsai-Yuan Hsieh, Kuo-Chih Tseng, Chih-Lin Lin, Tung-Hung Su, Tai-Chung Tseng, Hans Hsienhong Lin, Chia-Chi Wang, Jia-Horng Kao, HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients, Journal of the Formosan Medical Association, 2013,

    CrossRef

  11. 11
    Tarik Asselah, Patrick Marcellin, Long-term Results of Treatment with Nucleoside and Nucleotide Analogues (Entecavir and Tenofovir) for Chronic Hepatitis B, Clinics in Liver Disease, 2013, 17, 3, 445

    CrossRef

  12. 12
    Etienne M. Sokal, Massimiliano Paganelli, Stefan Wirth, Piotr Socha, Pietro Vajro, Florence Lacaille, Deirdre Kelly, Giorgina Mieli-Vergani, Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines, Journal of Hepatology, 2013, 59, 4, 814

    CrossRef

  13. 13
    Hee Yeon Kim, Jong Young Choi, Chung-Hwa Park, Jeong Won Jang, Chang Wook Kim, Si Hyun Bae, Seung Kew Yoon, Jin Mo Yang, Chang Don Lee, Young Sok Lee, Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus, Journal of Clinical Virology, 2013, 56, 4, 299

    CrossRef

  14. 14
    Jung Hyun Kwon, Jeong Won Jang, Jong Young Choi, Chung-Hwa Park, Sun Hong Yoo, Si Hyun Bae, Seung Kew Yoon, Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?, Journal of Medical Virology, 2013, 85, 1
  15. 15
    Weng Kai Chan, Soek-Siam Tan, Rosmawati Mohamed, Stopping Therapy in HBeAg Negative Disease, Current Hepatitis Reports, 2013, 12, 2, 105

    CrossRef

  16. 16
    Grace Lai-Hung Wong, Ching-Ning Chong, Vincent Wai-Sun Wong, Tertiary Prevention of HBV-related HCC in Asia, Current Hepatitis Reports, 2013, 12, 3, 157

    CrossRef

  17. You have free access to this content17
    Hong Ma, Jidong Jia, Why do I treat HBeAg-positive chronic hepatitis B patients with a Nucleoside analogue, Liver International, 2013, 33,
  18. 18
    Yun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, Henry Lik Yuen Chan, Rong-Nan Chien, Chun-Jen Liu, Ed Gane, Stephen Locarnini, Seng-Gee Lim, Kwang-Hyub Han, Deepak Amarapurkar, Graham Cooksley, Wasim Jafri, Rosmawati Mohamed, Jin-Lin Hou, Wan-Long Chuang, Laurentius A. Lesmana, Jose D. Sollano, Dong-Jin Suh, Masao Omata, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update, Hepatology International, 2012, 6, 3, 531

    CrossRef

  19. 19
    Young-Joo Jin, Kang Kim, Dong-jun Yoo, Ju Shim, Han Lee, Young-Hwa Chung, Yung Lee, Dong Suh, Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients, Virology Journal, 2012, 9, 1, 239

    CrossRef

  20. 20
    María Buti, Javier García-Samaniego, Martín Prieto, Manuel Rodríguez, José María Sánchez-Tapias, Emilio Suárez, Rafael Esteban, Documento de consenso de la AEEH sobre el tratamiento de la infección por el virus de la hepatitis B (2012), Gastroenterología y Hepatología, 2012, 35, 7, 512

    CrossRef

  21. 21
    Steven J. Scaglione, Anna S.F. Lok, Effectiveness of Hepatitis B Treatment in Clinical Practice, Gastroenterology, 2012, 142, 6, 1360

    CrossRef

  22. 22
    Tram T. Tran, High Frequency of Viremia After Hepatitis B e Antigen Seroconversion and Consolidation Therapy, Journal of Clinical Gastroenterology, 2012, 46, 10, 807

    CrossRef

  23. 23
    KASL Clinical Practice Guidelines: Management of chronic hepatitis B, Clinical and Molecular Hepatology, 2012, 18, 2, 109

    CrossRef

  24. 24
    Suk Jin Hong, Byung-Ho Choe, Strategy to Overcome Drug Resistance That Develops during Treatment of Chronic Hepatitis B in Children, Pediatric Gastroenterology, Hepatology & Nutrition, 2012, 15, 2, 63

    CrossRef

  25. 25
    Suk Jin Hong, Byung-Ho Choe, Strategy to Overcome Drug Resistance That Develops during Treatment of Chronic Hepatitis B in Children, Pediatric Gastroenterology, Hepatology & Nutrition, 2012, 15, 2, 63

    CrossRef

  26. 26
    T.-C. Tseng, C.-J. Liu, T.-H. Su, H.-C. Yang, C.-C. Wang, C.-L. Chen, S. F.-T. Kuo, C.-H. Liu, P.-J. Chen, D.-S. Chen, J.-H. Kao, Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation, Journal of Infectious Diseases, 2012, 206, 10, 1521

    CrossRef

  27. 27
    Anna S. F. Lok, Francesco Negro, Hepatitis B and D,
  28. 28
    Hellan K. Kwon, Anna S.F. Lok, Treatment of Hepatitis B,